Topiramate sprinkle is effective in the treatment of childhood epilepsy
Article Sidebar
Main Article Content
Abstract
Epilepsy remains one of the most frequently occurring pediatric problems. Approximately 10-15% patients do not respond to conventional therapy. Topiramate as a novel antiepileptic drug has a broad spectrum activity, presumably indicative of multiple anti-seizure mechanisms. Previous studies of topiramate as adjunctive and monotherapy in adults have shown beneficial effects. The objective of this research was to evaluate the efficacy and tolerability of topiramate sprinkle monotherapy in pediatric epilepsy.
Methods
This experimental research was conducted in the Pediatric Neurology outpatient clinic department, Soetomo hospital, Surabaya, involving 18 consecutive subjects. Subjects meeting the inclusion criteria were treated with topiramate sprinkle adjusted dose. Seizure frequency and side effects were observed in weeks 1, 4, 8, 12, 16, 20 and 24, respectively. Electro encephalogram (EEG) and laboratory examinations were performed prior to and after 6 months of treatment. The t-test for related samples and McNemar test were utilized for statistical analysis.
Results
A total of 15 subjects completed the study. Topiramate-treated patients showed a statistically significant difference of seizure frequency reduction from 2.7 ± 1.16 to 0.13 ± 0.51 (p=0.000) with 93.7% patients being seizure free in 20 weeks. EEG recordings did not differ statistically in decrement of epileptiform activity in 20% subjects. About 7% subjects developed drowsiness and 33.3% subjects suffered from appetite suppression in the initial treatment. Laboratory results showed no abnormalities.
Conclusions
There was reduction of seizure frequency and no EEG recording alterations after topiramate sprinkle monotherapy. Topiramate as a monotherapy is highly effcicacious in childhood epilepsy.
Article Details
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
References
Attumalil TV, Sundaram A, Varghese VO, Vijayakumar K, Kunju PA. Risk factors of childhood epilepsy in Kerala. Ann Indian Acad Neurol 2011;14:283–6.
Saharso D, Erny, Poerwadi T. Pedoman pengobatan epilepsi pada anak. In: Permono B, Soeparto P, Kaspan MF, Soegijanto S, Soejoso DA, Narendra MB, editors. Surabaya: Surabaya Intellectual Club;2002.p.131-53.
Das A, Balan S, Banerjee M, Radhakrishnan K. Drug resistance in epilepsy and the ABCB1 gene. the cilinical perspective. Indian J Hum Genet 2011;17:12-21.
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology 2004; 62:1252-60.
Gilliam FG, Veloso F, Bomhof MAM, Gazda SK, Biton V, Ter Bruggen JP, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003;60: 196-202.
Brigo F. New anti-epileptic drug; overcoming the limits of randomized controlled trial. Int J Evid Based Health 2011;9:440-3.
Faught E. Topiramate in the treatment of partial and generalized epilepsy. Neuropsychiatr Dis Treat 2007;3:811-21.
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblended randomized controlled trial. Lancet 2007;369: 1016-26.
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomized controlled trial. Lancet 2007;369:1000-15.
Kwon YS, Jun YH, Hong YJ, Son BK. Topiramate monotherapy in infantile spasm. Yonsei Med J 2006;47:498-504.
Valencia I, Fons C, Kothare SV, Khurana DS, Yum S, Hardison HH, et al. Efficacy and tolerability of topiramate in children younger than 2 years old. J Child Neurol 2005;20:667-70.
Glauser TA. Topiramate. Epilepsia 1999;40:71-80.
Kugler SL, Sachdeo RC. Topiramate efficacy in infancy. Pediatr Neurol 1998;19:320-2.
Cross JH. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 2002;11:406-10.
Biton V, Edwards KR, Montouris GD, Sackerllares JC, Harden CL, Kamin M. Topiramate titration and tolerability. Ann Pharmacol 2001;35:173-9.
Aidyn K. Utility of electroencepalography in the evaluation of common neurologic condition in children. J Child Neurol 2003;18:394-6.
Panayiotopoulos CP. The epilepsies, seizures, syndromes and management. Oxford: Bladon Medical Publishing;2005.p.100-25.
Crumrine PK.Management of seizures in Lennox Gastaut syndrome. Paediatr Drugs 2011; 13:107-18.
Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects. Br J Clin Pharmacol 2009;68:655-61.
Kim JM, Kwon S, Seo H, Choe BH, Cho MH, Park SP. Longterm effectiveness and tolerability of topiramate in children with epilepsy under the age of 2 years: 4 –year follow up. J Korean Med Sci 2009;24:1078-82.